Rociletinib

Rociletinib
Clinical data
Trade names	Xegafri
Other names	CO-1686, AVL-301
Routes of; administration	By mouth
ATC code	L01EB05 (WHO) ;
Identifiers
	IUPAC name N-(3-{[2-{[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)-4-pyrimidinyl]amino}phenyl)acrylamide;
CAS Number	1374640-70-6;
PubChem CID	57335384;
DrugBank	DB11907;
ChemSpider	30646712;
UNII	72AH61702G;
KEGG	D10858;
CompTox Dashboard (EPA)	DTXSID801025958 ;
Chemical and physical data
Formula	C27H28F3N7O3
Molar mass	555.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F;
	InChI InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35); Key:HUFOZJXAKZVRNJ-UHFFFAOYSA-N;

Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.^[1] It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer.^[1] In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency.^[1]

References